IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina (RAFEHELP)
This study has been completed.
Sponsor:
Sanofi
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00507845
First received: July 26, 2007
Last updated: April 16, 2009
Last verified: April 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary:
- To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients
Secondary:
- To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
| Condition | Intervention | Phase |
|---|---|---|
| Hypertension | Drug: Ramipril-Felodipine | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina |
Resource links provided by NLM:
Further study details as provided by Sanofi:
Primary Outcome Measures:
- Mean changes in Systolic Blood Pressure (SBP) [ Time Frame: from baseline to Week 8 ]
Secondary Outcome Measures:
- Mean changes in Diastolic Blood Pressure (DBP) [ Time Frame: from baseline to Week 8 ]
- Percentage of responders with regard to DBP and SBP [ Time Frame: comparison to baseline ]
- Adverse events [ Time Frame: After treatment and at each follow-up visit ]
| Enrollment: | 271 |
| Study Start Date: | June 2007 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Ramipril-Felodipine
Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
Other Name: Triacor
Eligibility| Ages Eligible for Study: | 21 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Outpatient
- Patients who couldn´t control their hypertension after 6 weeks of treatment with monotherapy (calcium blockers, beta blockers, diuretics, ACE inhibitors, AT2 blockers)(uncontrolled hypertension).
Exclusion Criteria:
- Already on fixed-dose combination treatment for hypertension
- Contraindication to angiotensin converting enzyme (ACE) inhibitors or CCB therapy
- Known hypersensitivity to felodipine (or other dihydropyridines), ramipril, other ACE or any of the excipients of ramipril felodipine.
- History of angioedema
- Unstable haemodynamic conditions: cardiovascular shock, untreated heart failure, acute myocardial infarction, unstable angina pectoris, stroke.
- Patients with AV block II or III
- Severely impaired hepatic function.
- Pre-existing bilateral renal artery stenosis or stenosis of the artery to a solitary kidney
- Pregnant and lactating mothers
- Patients on dialysis or haemofiltration.
- Patients with creatinine clearance < 20ml/min
- Use of potassium sparing diuretics
- Severe hypertension (SBP ≥ 180 mmhg or DBP ≥ 110 mmhg)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507845
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507845
Locations
| Argentina | |
| Sanofi-aventis administrative office | |
| Buenos Aires, Argentina | |
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Cristian von Schulz Hausmann, MD | Sanofi |
More Information
| Responsible Party: | Medical Affairs Study Director, sanofi-aventis |
| ClinicalTrials.gov Identifier: | NCT00507845 History of Changes |
| Other Study ID Numbers: |
RAMIP_L_01961 |
| Study First Received: | July 26, 2007 |
| Last Updated: | April 16, 2009 |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases Ramipril Felodipine Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antihypertensive Agents Anti-Arrhythmia Agents Calcium Channel Blockers Membrane Transport Modulators Vasodilator Agents |
ClinicalTrials.gov processed this record on August 21, 2017